Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | SETDB1 | Q15047 | 4/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.43 |
| ▸ | TERT | O14746 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16133677 | 0.85 | MAPT (0.45) | TERTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL16768696 | 0.80 | TERT (0.34) | MTNR1AMTNR1BTERTALDH1A1SMN1; SMN2 | |
| SCHEMBL20180777 | 0.78 | TLR8 (0.41) | ALDH1A1 | |
| SCHEMBL31211330 | 0.78 | SETDB1 (0.48) | NPSR1SETDB1MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL16136311 | 0.76 | SETDB1 (0.41) | NPSR1SETDB1NQO2MTNR1AMTNR1B | |
| SCHEMBL16136313 | 0.76 | NPSR1 (0.40) | NPSR1SETDB1NQO2MTNR1AMTNR1B | |
| SCHEMBL22946629 | 0.75 | POLB (0.45) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL15906405 | 0.73 | PSEN1 (0.34) | ALDH1A1 | |
| SCHEMBL8470999 | 0.72 | RAB9A (0.58) | SETDB1ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL27171015 | 0.72 | PARP1 (0.44) | NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776996-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160326170-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2016-11-10 | — | — | US | disclosed |
| US-9365570-B2 | Substituted 6, 5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160024081-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2016-01-28 | — | — | US | disclosed |
| US-20150246916-A1 | Substituted 6, 5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2015-09-03 | — | — | US | disclosed |
| US-9045477-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140296283-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024081-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | NPSR1 2400/4885SETDB1 3985/4885NQO2 156/4885 |
| US-20150246916-A1 | Substituted 6, 5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | NPSR1 2400/4885SETDB1 3985/4885NQO2 156/4885 |
| US-20140296283-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | NPSR1 2400/4885SETDB1 3985/4885NQO2 156/4885 |
| US-20160326170-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | CYP3A5, PAICS, CYP4B1 | NPSR1 2400/4885SETDB1 3985/4885NQO2 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.